Stockscreener 앱 받기
20.01
2.88%
0.56
시간 외 거래:
20.03
0.02
+0.10%
전일 마감가:
$19.45
열려 있는:
$19.17
하루 거래량:
237.55K
Relative Volume:
0.78
시가총액:
$1.36B
수익:
$350.00K
순이익/손실:
$-72.78M
주가수익비율:
-18.53
EPS:
-1.08
순현금흐름:
$-54.46M
1주 성능:
+10.55%
1개월 성능:
-20.75%
6개월 성능:
+32.52%
1년 성능:
+16.74%
1일 변동 폭
$18.68
$20.21
1주일 범위
$17.62
$20.21
52주 변동 폭
$12.56
$26.30
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
20.01 | 1.32B | 350.00K | -72.78M | -54.46M | -1.08 |
|
ISRG
Intuitive Surgical Inc
|
492.87 | 172.54B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
163.17 | 46.62B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
80.77 | 39.31B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
RMD
Resmed Inc
|
240.15 | 36.00B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
42.39 | 34.80B | 28.43B | 1.16B | 1.26B | 1.4457 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Mizuho | Outperform |
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
Pulse Biosciences (NASDAQ:PLSE) Trading 8% HigherWhat's Next? - MarketBeat
Breakout Move: Can Pulse Biosciences Inc continue delivering strong returnsMarket Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Pulse Biosciences (PLSE) Reports Promising Long-Term Outcomes fo - GuruFocus
Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn - TipRanks
Pulse Biosciences Announces Long-Term Clinical Data for nPulse Vybrance Percutaneous Electrode System in Benign Thyroid Nodule Ablation 71314 - Minichart
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Investing News Network
Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results - TipRanks
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Business Wire
Why Pulse Biosciences Inc. stock could be next big winnerEarnings Recap Summary & Fast Entry and Exit Trade Plans - Naître et grandir
How strong is Pulse Biosciences Inc. (6L8) stock earnings growthDividend Hike & Low Volatility Stock Recommendations - Naître et grandir
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Momentum - simplywall.st
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - The Joplin Globe
Pulse Biosciences at TD Cowen Conference: NSPFA Technology Shines - Investing.com
Thyroid experts review 15–22 month data on Pulse nPulse ablation - Stock Titan
PLSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulse Biosciences (NASDAQ:PLSE) Stock Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Pulse Biosciences Highlights nPulse Cardiac Ablation Progress - TipRanks
Pulse Biosciences posts updated investor deck highlighting nPulse cardiac catheter and strengthened EP focus - TradingView
Pulse Biosciences (NASDAQ: PLSE) releases updated March 2026 investor deck - Stock Titan
Pulse Biosciences, Inc (PLSE) Stock Analysis: Is A 59% Upside Within Reach? - DirectorsTalk Interviews
Market Wrap: Does Pulse Biosciences Inc have strong fundamentalsWeekly Earnings Recap & Weekly Top Stock Performers List - baoquankhu1.vn
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE) clarifies disclosure on CCO Kevin Danahy’s resignation - Stock Titan
Pulse Biosciences Executive Sells 60,000 Shares - TradingView
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And Cash Flow Forecasts? - Yahoo Finance
Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding PlansHas The Bull Case Changed? - simplywall.st
Pulse Biosciences chief commercial officer resigns effective immediately - Investing.com Nigeria
PLSE Should I Buy - Intellectia AI
Pulse Biosciences Announces Resignation of Chief Commercial Officer - TipRanks
Chief Commercial Officer exits Pulse Biosciences (PLSE) with no stated dispute - Stock Titan
US med-tech companies bullish about 2026 - bioworld.com
Is Pulse Biosciences (PLSE) Share Price Justified After Recent Volatility In Healthcare Sentiment - simplywall.st
Pulse Biosciences (PLSE) Price Target Increased by 27.66% to 30.60 - Nasdaq
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 48.59% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ETF Watch: Will Perfect Corp Equity Warrant face regulatory challenges2025 Stock Rankings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Pulse Biosciences CCO Danahy sells $118k in PLSE stock By Investing.com - Investing.com Canada
Kevin Patrick Danahy Sells 5,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock - MarketBeat
Pulse Biosciences (PLSE) CCO exercises options and sells 5,000 shares - Stock Titan
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2026 - BioSpace
Aug EndMonth: Is Pulse Biosciences Inc benefiting from innovation trendsTrade Entry Summary & Smart Swing Trading Techniques - baoquankhu1.vn
Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Pulse Biosciences (NASDAQ:PLSE) Shares Down 6.5%Here's Why - MarketBeat
Pulse Biosciences slips despite Q4 beat after deal to sell shares - MSN
Pulse Biosciences Inc (PLSE) Shares Gap Down to $22.02 on Feb 20 - GuruFocus
Oppenheimer raises Pulse Biosciences stock price target to $30 By Investing.com - Investing.com Canada
Pulse Biosciences stock slips despite Q4 beat (PLSE:NASDAQ) - Seeking Alpha
Pulse Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference - The AI Journal
Decoding Pulse Biosciences Inc (PLSE): A Strategic SWOT Insight - GuruFocus
Pulse Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.89%
자본화:
|
볼륨(24시간):